Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
- 1 January 2002
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 18 (6)
- https://doi.org/10.1185/030079902125000949
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with DonepezilCurrent Medical Research and Opinion, 2002
- A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate ADNeurology, 2001
- Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer DiseaseArchives of Neurology, 2001
- The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1Dementia and Geriatric Cognitive Disorders, 1999
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998